Results 71 to 80 of about 1,927 (159)

Physiologically Based Pharmacokinetic Modelling of UGT Substrate Drugs Lamotrigine and Raltegravir during Pregnancy

Future Pharmacology
Pregnancy is associated with various physiological changes that can significantly impact the disposition of drugs. To further the insight into how pregnancy affects the pharmacokinetics of drugs at different stages, clinical studies can be simulated ...
Monika Berezowska, Paola Coppola, Venkatesh Pilla Reddy, Pradeep Sharma   +3 more
doaj   +1 more source

Maraviroc and raltegravir [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A. Dubois, Adam F. Cohen
openaire   +2 more sources

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study

AIDS Research and Therapy, 2020
Background In resource-limited settings, multi-experienced HIV infected patients are often prescribed raltegravir for salvage therapy. Patients failing raltegravir-containing regimens require other drugs including other integrase inhibitors.
Aurelio Orta-Resendiz, Roberto A. Rodriguez-Diaz, Luis A. Angulo-Medina, Mario Hernandez-Flores, Luis E. Soto-Ramirez   +4 more
doaj   +1 more source

Raltegravir in the management of HIV-infected patients

Drug Design, Development and Therapy, 2008
Raltegravir has recently been licensed for the treatment of HIV-1 infection. Currently its use is limited to treatment-experienced patients and subjects with resistant virus. In addition to its activity in the setting of resistance and treatment failure, it appears to have great potential for first-line therapy and as a switch option for subjects with ...
openaire   +5 more sources

Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy

Retrovirology, 2010
Background In this study we successfully created a new approach to ART in SIVmac251 infected nonhuman primates. This drug regimen is entirely based on drugs affecting the pre-integration stages of replication and consists of only two nucleotidic ...
Greenhouse Jack, Yalley-Ogunro Jake, Chirullo Barbara, Iraci Nunzio, Collins Matt, Barreca Maria, Norelli Sandro, Lewis Mark G, Titti Fausto, Garaci Enrico, Savarino Andrea   +10 more
doaj   +1 more source

Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance

Retrovirology, 2018
Background Emergence of resistance against integrase inhibitor raltegravir in human immunodeficiency virus type 1 (HIV-1) patients is generally associated with selection of one of three signature mutations: Y143C/R, Q148K/H/R or N155H, representing three
Axel Fun, Thomas Leitner, Linos Vandekerckhove, Martin Däumer, Alexander Thielen, Bernd Buchholz, Andy I. M. Hoepelman, Elizabeth H. Gisolf, Pauline J. Schipper, Annemarie M. J. Wensing, Monique Nijhuis   +10 more
doaj   +1 more source

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

Malaria Journal, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Ivanovic Jelena, Gallo Anna L, D'Avolio Antonio, Tempestilli Massimo, Bellagamba Rita, Tommasi Chiara, Nicastri Emanuele, Pucillo Leopoldo P, Narciso Pasquale   +8 more
doaj   +1 more source

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro [PDF]

, 2008
Isabelle Malet, Olivier Delelis, Marc‐Antoine Valantin, Brigitte Montès, Cathia Soulié, Marc Wirden, Luba Tchertanov, Gilles Peytavin, Jacques Reynes, Jean‐François Mouscadet, Christine Katlama, Vincent Cálvez, Anne‐Geneviève Marcelin   +12 more
openalex   +1 more source

Investigating Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) reported in association with HIV antiretroviral therapy: An analysis of the FDA Adverse Event Reporting System

JEADV Clinical Practice, Volume 3, Issue 5, Page 1701-1704, December 2024.
Bianca E. Ituarte, Mitchell A. Taylor, Erin X. Wei, Jennifer Adams   +3 more
wiley   +1 more source

Raltegravir: a potent and safe integrase inhibitor with a favourable impact on cardiovascular and liver profile [PDF]

, 2008
Francisco J. Blanco, Miguel Arredondo, Freddy Guevara, Carmen Garrido, Judit Morelló, Sonia Rodríguez‐Nóvoa, Mònica Córdoba, Juan González‐Lahoz, Vincent Soriano   +8 more
openalex   +1 more source